☆ 4.8 Editorial Material

Time for a new obesity narrative

LANCET (2018)

Get Full Text
Add to Collection

Journal

LANCET
Volume 392, Issue 10156, Pages 1384-1386

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(18)32537-6

Keywords

-

Categories

Medicine, General & Internal

Funding

  1. Novo Nordisk
  2. SFI
  3. BMS
  4. Zafgen
  5. Australian Eggs
  6. Servier Laboratories (Aust)
  7. Ache Pharmaceuticals
  8. Valeant Canada
  9. Novartis
  10. Amgen
  11. Eisai
  12. Real Appeal
  13. Orexigen
  14. Sanofi
  15. Janssen
  16. Takeda
  17. Pfizer
  18. Baro Nova (Data Safety Monitoring Board)
  19. Gila Therapeutics
  20. Scientific Intake
  21. Epitomee
  22. AstraZeneca
  23. Boehringer Ingelheim
  24. Lilly
  25. Napp
  26. Wilmington Healthcare
  27. Biologix

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.